These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23548649)

  • 21. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
    Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
    Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer.
    Seo MK; Cairns J
    PLoS One; 2018; 13(9):e0204496. PubMed ID: 30256829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer].
    Pericay C; Frías C; Abad A; Lamas MJ; Echave M; Oyagüez I; Rubio M; Giménez E; Naoshy S; Joulain F
    Farm Hosp; 2014 Jul; 38(4):317-27. PubMed ID: 25137165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis.
    Goldstein DA; Chen Q; Ayer T; Chan KKW; Virik K; Hammerman A; Brenner B; Flowers CR; Hall PS
    Oncologist; 2017 Jun; 22(6):694-699. PubMed ID: 28592621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analyses of osteoarthritis oral therapies: a systematic review.
    Wielage RC; Myers JA; Klein RW; Happich M
    Appl Health Econ Health Policy; 2013 Dec; 11(6):593-618. PubMed ID: 24214160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis.
    Norum J
    J Chemother; 2006 Oct; 18(5):532-7. PubMed ID: 17127231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The quality of reporting in published cost-utility analyses, 1976-1997.
    Neumann PJ; Stone PW; Chapman RH; Sandberg EA; Bell CM
    Ann Intern Med; 2000 Jun; 132(12):964-72. PubMed ID: 10858180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A critical review of the full economic evaluations of pharmacological treatments for colorectal cancer.
    Garattini L; Compadri PD; Koleva D; Pasina L; Nobili A
    J Med Econ; 2008; 11(1):177-97. PubMed ID: 19450119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations.
    Velentzis LS; Salagame U; Canfell K
    BMC Health Serv Res; 2017 May; 17(1):326. PubMed ID: 28476121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.
    Riesco-Martínez MC; Berry SR; Ko YJ; Mittmann N; Giotis A; Lien K; Wong WW; Chan KK
    J Oncol Pract; 2016 Jun; 12(6):e710-23. PubMed ID: 27143148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of number needed to treat in cost-effectiveness analyses.
    Garg V; Shen X; Cheng Y; Nawarskas JJ; Raisch DW
    Ann Pharmacother; 2013 Mar; 47(3):380-7. PubMed ID: 23463742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
    Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
    Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-utility analysis in spine care: a systematic review.
    Kepler CK; Wilkinson SM; Radcliff KE; Vaccaro AR; Anderson DG; Hilibrand AS; Albert TJ; Rihn JA
    Spine J; 2012 Aug; 12(8):676-90. PubMed ID: 22784806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
    Poonawalla IB; Parikh RC; Du XL; VonVille HM; Lairson DR
    Pharmacoeconomics; 2015 Nov; 33(11):1155-85. PubMed ID: 26072142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
    Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
    J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety and effectiveness of different methods of earwax removal: a systematic review and economic evaluation.
    Clegg AJ; Loveman E; Gospodarevskaya E; Harris P; Bird A; Bryant J; Scott DA; Davidson P; Little P; Coppin R
    Health Technol Assess; 2010 Jun; 14(28):1-192. PubMed ID: 20546687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.